INDIA MARKET LENS

Apollo Hospitals Enterprise Limited (APOLLOHOSP): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Apollo Hospitals Enterprise Limited, explained in plain English.

  • Apollo Hospitals Enterprise Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
  • APOLLOHOSP closed at ₹9,200.00 on 20 November 2026.
  • Over the past year the shares are up 24.5%, trading between ₹6,696.50 and ₹9,282.50.
  • Reported fundamentals show return on equity of 22.53%, a net margin of 8.05%, debt to equity of 73.04.
  • Our Pulse grade checklist scores it C (60/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
  • Annualised volatility over the past year is 21.92% with a maximum drawdown of -16.2% and a beta of 0.53 against NIFTY 50.
  • Recent coverage: Apollo's Bangladesh patient revenue nears pre-crisis peak of ₹450 crore

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Aster DM Quality Care, Aurobindo Pharma, Biocon

Last traded values from 20 Nov 2026. Closed — weekend.

Apollo Hospitals Enterprise Limited (APOLLOHOSP)

₹8,738

▼ 83 (-0.94%)

Price & volume

APOLLOHOSP price chart, 1Y range. 252 points from 2025-11-24 to 2026-11-19. Opens at 7,354.5, closes at 8,738, ranging between 6,793.5 and 9,069.7,0008,0009,000Nov-25Jan-26Mar-26May-26Jun-26Aug-26Sep-26Nov-26volume

Hover for exact price & volume · green/red volume bars show up vs down days

Strong momentum · 4/5
✓ Above 50-day avg✓ Above 200-day avgRSI 61.2 · healthyMACD positiveBollinger %B 77ADX 18.7 · weak trend

1M

+13.48%

3M

-0.14%

6M

+8.87%

1Y

+17.15%

Where it sits in its 52-week range

85%
₹6,793.5₹9,069

Below 52-week high

3.6%

28.6% above the low

Momentum read

Strong

4/5 checks passed

52-wk high

₹9,069

52-wk low

₹6,793.5

Market cap

₹1,25,639 Cr

P/E (trailing)

55.9

Dividend yield

—

ROE

22.53%

Profit margin

8.05%

Revenue growth

20.8%

Price / Book

11.85

Debt / Equity

73.04

EPS (TTM)

156.39

Book value

₹737.64

Beta

0.5

Pulse grade: C, 60 out of 100

Momentum

B
  • ✓Trading above 50-day average
  • ✓Trading above 200-day average
  • ✓RSI in healthy 45-70 zone
  • ✕Positive 3-month return

Growth

C
  • ✕Revenue growth above Pharma & Healthcare median (20.8%)
  • ✓Revenue growing above 5%
  • ✓Quarterly profits trending up

Profitability

C
  • ✓Return on equity above Pharma & Healthcare median (14.45%)
  • ✓Return on equity above 12%
  • ✕Profit margin above Pharma & Healthcare median (14.2%)

Safety

D
  • ✕Debt below Pharma & Healthcare median (17.71)
  • ✓Debt not extreme for the sector
  • ✓Less volatile than the market (beta < 1.2)
  • ✕Pays a dividend

Quarterly revenue vs net profit

Revenue Net profit₹ crore, by quarter

Sep 2026: revenue ₹7,615 crore · net profit ₹630 crore · margin 8.3%

7,6150Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026

Business quality

Intrinsic value

Building the model…

Analyst coverage

Who owns this company

Events, dividends & splits

Market position

Pharma & Healthcare sector

PeerPrice ₹Day changeFrom 52-wk high
SUNPHARMA1,900+1.52%-5.05%
DRREDDY1,400.9+0.19%0.00%
CIPLA1,418.5+0.11%-7.37%
DIVISLAB11,178+1.17%-3.35%
LUPIN1,998.8+1.36%-20.52%
AUROPHARMA1,805.7+0.52%-2.67%

APOLLOHOSP headlines

No APOLLOHOSP stories right now.

APOLLOHOSP filings & announcements

Reading the exchange…

APOLLOHOSP, historical timeline

The timeline will be ready shortly

The rest of the page is unaffected.

Risk & return, last 12 months

Volatility (ann.)

21.3%

Sharpe ratio

0.62

Sortino ratio

0.95

Max drawdown

-16.2%

Daily VaR (95%)

-1.78%

CAGR (1Y)

18.89%

Return skew

0.24

Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.

Risk profile over time

Quant tearsheet

Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.